Physician profile
Thomas Walsh
NPI 1215074612
$2,220.64
in general payments reported to CMS, 2019-2025
11 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2021: $111 · 2022: $330 · 2023: $573 · 2024: $238 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $932.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $425.44 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.19 | 2019 | |
| United Therapeutics Corporation | $297.83 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $246.78 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $239.38 | 2023-2025 | Tezspire |
| Genzyme Corporation | $237.92 | 2024 | |
| Mylan Specialty L.P. | $124.99 | 2023 | Yupelri |
| Amgen INC. | $118.05 | 2023 | Tezspire |
| Glaxosmithkline, LLC. | $94.72 | 2023 | |
| Electromed, INC. | $71.07 | 2022 | |
| Grifols USA, LLC | $61.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.